Ahmed SMU, Luo L, Namani A et al (2017) Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis 1863:585–597. 10.1016/j.bbadis.2016.11.005 DOI: 10.1016/j.bbadis.2016.11.005
Antonini A, Jenner P (2018) Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14:693–694. 10.1038/s41582-018-0083-y DOI: 10.1038/s41582-018-0083-y
Bahn G, Jo D-G (2019) Therapeutic approaches to Alzheimer’s disease through modulation of NRF2. Neuromolecular Med 21:1–11. 10.1007/s12017-018-08523-5 DOI: 10.1007/s12017-018-08523-5
Bellezza I, Tucci A, Galli F et al (2012) Inhibition of NF-κB nuclear translocation via HO-1 activation underlies α-tocopheryl succinate toxicity. J Nutr Biochem 23:1583–1591. 10.1016/j.jnutbio.2011.10.012 DOI: 10.1016/j.jnutbio.2011.10.012
Block ML, Hong J-S (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35:1127–1132. 10.1042/BST0351127 DOI: 10.1042/BST0351127
Block ML, Zecca L, Hong J-S (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69. 10.1038/nrn2038 DOI: 10.1038/nrn2038
Boettler U, Sommerfeld K, Volz N et al (2011) Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-dependent gene expression. J Nutr Biochem 22:426–440. 10.1016/j.jnutbio.2010.03.011 DOI: 10.1016/j.jnutbio.2010.03.011
Boyle A, Ondo W (2015) Role of apomorphine in the treatment of Parkinson’s disease. CNS Drugs 29:83–89. 10.1007/s40263-014-0221-z DOI: 10.1007/s40263-014-0221-z
Brandes MS, Gray NE (2020) NRF2 as a therapeutic target in neurodegenerative diseases. ASN Neuro 12:1759091419899782. 10.1177/1759091419899782 DOI: 10.1177/1759091419899782
Cahill E, Salery M, Vanhoutte P, Caboche J (2014) Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse. Front Pharmacol 4:172. 10.3389/fphar.2013.00172 DOI: 10.3389/fphar.2013.00172
Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs 33:905–918. 10.1007/s40263-019-00661-z DOI: 10.1007/s40263-019-00661-z
Chen W-W, Zhang X, Huang W-J (2016) Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 13:3391–3396. 10.3892/mmr.2016.4948 DOI: 10.3892/mmr.2016.4948
Cuadrado A, Manda G, Hassan A et al (2018) Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol Rev 70:348–383. 10.1124/pr.117.014753 DOI: 10.1124/pr.117.014753
Cuenca L, Gil-Martinez AL, Cano-Fernandez L et al (2019) Parkinson’s disease: a short story of 200 years. Histol Histopathol 34:573–591. 10.14670/HH-18-073 DOI: 10.14670/HH-18-073
Deshmukh P, Unni S, Krishnappa G, Padmanabhan B (2017) The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev 9:41–56. 10.1007/s12551-016-0244-4 DOI: 10.1007/s12551-016-0244-4
Dinkova-Kostova AT, Kostov RV, Kazantsev AG (2018) The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J 285:3576–3590. 10.1111/febs.14379 DOI: 10.1111/febs.14379
Dominguez-Meijide A, Rodriguez-Perez AI, Diaz-Ruiz C et al (2017) Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures. Brain Behav Immun 62:277–290. 10.1016/j.bbi.2017.02.013 DOI: 10.1016/j.bbi.2017.02.013
Duffy MF, Collier TJ, Patterson JR et al (2018) Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation 15:129. 10.1186/s12974-018-1171-z DOI: 10.1186/s12974-018-1171-z
Ekdahl CT, Kokaia Z, Lindvall O (2009) Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 158:1021–1029. 10.1016/j.neuroscience.2008.06.052 DOI: 10.1016/j.neuroscience.2008.06.052
El-Bachá RS, Leclerc S, Netter P et al (2000) Glucuronidation of apomorphine. Life Sci 67:1735–1745. 10.1016/s0024-3205(00)00764-5 DOI: 10.1016/s0024-3205(00)00764-5
Fan Y, Chen Z, Pathak JL et al (2018) Differential regulation of adhesion and phagocytosis of resting and activated microglia by dopamine. Front Cell Neurosci 12:309. 10.3389/fncel.2018.00309 DOI: 10.3389/fncel.2018.00309
Färber K, Pannasch U, Kettenmann H (2005) Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol Cell Neurosci 29:128–138. 10.1016/j.mcn.2005.01.003 DOI: 10.1016/j.mcn.2005.01.003
Gassen M, Glinka Y, Pinchasi B, Youdim MB (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308:219–225. 10.1016/0014-2999(96)00291-9 DOI: 10.1016/0014-2999(96)00291-9
Gelders G, Baekelandt V, Van der Perren A (2018) Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J Immunol Res 2018:4784268. 10.1155/2018/4784268 DOI: 10.1155/2018/4784268
Grozdanov V, Bousset L, Hoffmeister M et al (2019) Increased Immune activation by pathologic α-synuclein in Parkinson’s disease. Ann Neurol 86:593–606. 10.1002/ana.25557 DOI: 10.1002/ana.25557
Grünblatt E, Mandel S, Gassen M, Youdim MB (1999) Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl 55:57–70. 10.1007/978-3-7091-6369-6_6 DOI: 10.1007/978-3-7091-6369-6_6
Grünblatt E, Mandel S, Maor G, Youdim MB (2001) Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J Neurochem 77:146–156. 10.1046/j.1471-4159.2001.t01-1-00227.x DOI: 10.1046/j.1471-4159.2001.t01-1-00227.x
Gurevich EV, Gainetdinov RR, Gurevich VV (2016) G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharmacol Res 111:1–16. 10.1016/j.phrs.2016.05.010 DOI: 10.1016/j.phrs.2016.05.010
Han M, Hu L, Chen Y (2019) Rutaecarpine may improve neuronal injury, inhibits apoptosis, inflammation and oxidative stress by regulating the expression of ERK1/2 and Nrf2/HO-1 pathway in rats with cerebral ischemia-reperfusion injury. Drug Des Devel Ther 13:2923–2931. 10.2147/DDDT.S216156 DOI: 10.2147/DDDT.S216156
Hara H, Ohta M, Adachi T (2006) Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 84:860–866. 10.1002/jnr.20974 DOI: 10.1002/jnr.20974
Harry GJ (2013) Microglia during development and aging. Pharmacol Ther 139:313–326. 10.1016/j.pharmthera.2013.04.013 DOI: 10.1016/j.pharmthera.2013.04.013
Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199–218. 10.1016/j.tibs.2014.02.002 DOI: 10.1016/j.tibs.2014.02.002
Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT (2010) Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 13:1713–1748. 10.1089/ars.2010.3221 DOI: 10.1089/ars.2010.3221
Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19:610–621. 10.1038/s41583-018-0055-7 DOI: 10.1038/s41583-018-0055-7
Hoenen C, Gustin A, Birck C et al (2016) Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS ONE 11:e0162717. 10.1371/journal.pone.0162717 DOI: 10.1371/journal.pone.0162717
Huck JHJ, Freyer D, Böttcher C et al (2015) De novo expression of dopamine D2 receptors on microglia after stroke. J Cereb Blood Flow Metab 35:1804–1811. 10.1038/jcbfm.2015.128 DOI: 10.1038/jcbfm.2015.128
Hybertson BM, Gao B (2014) Role of the Nrf2 signaling system in health and disease. Clin Genet 86:447–452. 10.1111/cge.12474 DOI: 10.1111/cge.12474
Innamorato NG, Rojo AI, García-Yagüe AJ et al (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol Baltim Md 181:680–689. 10.4049/jimmunol.181.1.680 DOI: 10.4049/jimmunol.181.1.680
Jenner P, Katzenschlager R (2016) Apomorphine—pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord 33(Suppl 1):S13–S21. 10.1016/j.parkreldis.2016.12.003 DOI: 10.1016/j.parkreldis.2016.12.003
Johnson JA, Johnson DA, Kraft AD et al (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147:61–69. 10.1196/annals.1427.036 DOI: 10.1196/annals.1427.036
Kalkman HO, Feuerbach D (2016) Antidepressant therapies inhibit inflammation and microglial M1-polarization. Pharmacol Ther 163:82–93. 10.1016/j.pharmthera.2016.04.001 DOI: 10.1016/j.pharmthera.2016.04.001
Kansanen E, Kuosmanen SM, Leinonen H, Levonen A-L (2013) The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 1:45–49. 10.1016/j.redox.2012.10.001 DOI: 10.1016/j.redox.2012.10.001
Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759. 10.1016/S1474-4422(18)30239-4 DOI: 10.1016/S1474-4422(18)30239-4
Kaul PN, Brochmann-Hanssen E (1961) Auto-oxidation of apomorphine. J Pharm Sci 50:266–267. 10.1002/jps.2600500323 DOI: 10.1002/jps.2600500323
Kempuraj D, Thangavel R, Selvakumar GP et al (2017) Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration. Front Cell Neurosci 11:216. 10.3389/fncel.2017.00216 DOI: 10.3389/fncel.2017.00216
Kempuraj D, Thangavel R, Natteru PA et al (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1:1003
Kim M-O, Si Q, Zhou JN et al (2002) Interferon-beta activates multiple signaling cascades in primary human microglia. J Neurochem 81:1361–1371. 10.1046/j.1471-4159.2002.00949.x DOI: 10.1046/j.1471-4159.2002.00949.x
Kim HN, Kim JD, Park SB et al (2020) Anti-inflammatory activity of the extracts from Rodgersia podophylla leaves through activation of Nrf2/HO-1 pathway, and inhibition of NF-κB and MAPKs pathway in mouse macrophage cells. Inflamm Res off J Eur Histamine Res Soc Al 69:233–244. 10.1007/s00011-019-01311-2 DOI: 10.1007/s00011-019-01311-2
Kobayashi EH, Suzuki T, Funayama R et al (2016) Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7:11624. 10.1038/ncomms11624 DOI: 10.1038/ncomms11624
Lastres-Becker I, García-Yagüe AJ, Scannevin RH et al (2016) Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson’s disease. Antioxid Redox Signal 25:61–77. 10.1089/ars.2015.6549 DOI: 10.1089/ars.2015.6549
LeWitt PA, Fahn S (2016) Levodopa therapy for Parkinson disease: a look backward and forward. Neurology 86:S3-12. 10.1212/WNL.0000000000002509 DOI: 10.1212/WNL.0000000000002509
Li A, Guo H, Luo X et al (2006) Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. FASEB 20:1263–1265. 10.1096/fj.05-5510fje DOI: 10.1096/fj.05-5510fje
Liu L, Kelly MG, Yang XR et al (2020) Nrf2 deficiency exacerbates cognitive impairment and reactive microgliosis in a lipopolysaccharide-induced neuroinflammatory mouse model. Cell Mol Neurobiol. 10.1007/s10571-020-00807-4 DOI: 10.1007/s10571-020-00807-4
Loboda A, Damulewicz M, Pyza E et al (2016) Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci 73:3221–3247. 10.1007/s00018-016-2223-0 DOI: 10.1007/s00018-016-2223-0
Losciuto S, Dorban G, Gabel S et al (2012) An efficient method to limit microglia-dependent effects in astroglial cultures. J Neurosci Methods 207:59–71. 10.1016/j.jneumeth.2012.03.010 DOI: 10.1016/j.jneumeth.2012.03.010
Lull ME, Block ML (2010) Microglial activation and chronic neurodegeneration. Neurother J Am Soc Exp Neurother 7:354–365. 10.1016/j.nurt.2010.05.014 DOI: 10.1016/j.nurt.2010.05.014
Lunati A, Lesage S, Brice A (2018) The genetic landscape of Parkinson’s disease. Rev Neurol (Paris) 174:628–643. 10.1016/j.neurol.2018.08.004 DOI: 10.1016/j.neurol.2018.08.004
Lundblad M, Decressac M, Mattsson B, Björklund A (2012) Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 109:3213–3219. 10.1073/pnas.1200575109 DOI: 10.1073/pnas.1200575109
Malhotra D, Portales-Casamar E, Singh A et al (2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38:5718–5734. 10.1093/nar/gkq212 DOI: 10.1093/nar/gkq212
Mariani L-L, Longueville S, Girault J-A et al (2019) Differential enhancement of ERK, PKA and Ca2+ signaling in direct and indirect striatal neurons of Parkinsonian mice. Neurobiol Dis 130:104506. 10.1016/j.nbd.2019.104506 DOI: 10.1016/j.nbd.2019.104506
Mead RJ, Higginbottom A, Allen SP et al (2013) S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic Biol Med 61:438–452. 10.1016/j.freeradbiomed.2013.04.018 DOI: 10.1016/j.freeradbiomed.2013.04.018
Mishra A, Singh S, Shukla S (2018) Physiological and functional basis of dopamine receptors and their role in neurogenesis: possible implication for Parkinson’s disease. J Exp Neurosci. 10.1177/1179069518779829 DOI: 10.1177/1179069518779829
Missale C, Nash SR, Robinson SW et al (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189–225. 10.1152/physrev.1998.78.1.189 DOI: 10.1152/physrev.1998.78.1.189
Papp D, Lenti K, Módos D et al (2012) The NRF2-related interactome and regulome contain multifunctional proteins and fine-tuned autoregulatory loops. FEBS Lett 586:1795–1802. 10.1016/j.febslet.2012.05.016 DOI: 10.1016/j.febslet.2012.05.016
Perry VH (2012) Innate inflammation in Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009373. 10.1101/cshperspect.a009373 DOI: 10.1101/cshperspect.a009373
Pessoa RR, Moro A, Munhoz RP et al (2018) Apomorphine in the treatment of Parkinson’s disease: a review. Arq Neuropsiquiatr 76:840–848. 10.1590/0004-282X20180140 DOI: 10.1590/0004-282X20180140
Petrillo S, Schirinzi T, Di Lazzaro G et al (2020) Systemic activation of Nrf2 pathway in Parkinson’s disease. Mov Disord off J Mov Disord Soc 35:180–184. 10.1002/mds.27878 DOI: 10.1002/mds.27878
Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047. 10.1126/science.276.5321.2045 DOI: 10.1126/science.276.5321.2045
Rascol O, Payoux P, Ory F et al (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53(Suppl 3):S3-12. 10.1002/ana.10513 DOI: 10.1002/ana.10513
Ribarič S (2012) The pharmacological properties and therapeutic use of apomorphine. Mol Basel Switz 17:5289–5309. 10.3390/molecules17055289 DOI: 10.3390/molecules17055289
Sandberg M, Patil J, D’Angelo B et al (2014) NRF2-regulation in brain health and disease: implication of cerebral inflammation. Neuropharmacology 79:298–306. 10.1016/j.neuropharm.2013.11.004 DOI: 10.1016/j.neuropharm.2013.11.004
Schneider SA, Alcalay RN (2017) Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov Disord off J Mov Disord Soc 32:1504–1523. 10.1002/mds.27193 DOI: 10.1002/mds.27193
Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 56:251–253
Singh S, Mishra A, Srivastava N et al (2018) Acetyl-L-Carnitine via upegulating dopamine D1 receptor and attenuating microglial activation prevents neuronal loss and improves memory functions in Parkinsonian rats. Mol Neurobiol 55:583–602. 10.1007/s12035-016-0293-5 DOI: 10.1007/s12035-016-0293-5
Sivandzade F, Bhalerao A, Cucullo L (2019a) Cerebrovascular and neurological disorders: protective role of NRF2. Int J Mol Sci. 10.3390/ijms20143433 DOI: 10.3390/ijms20143433
Sivandzade F, Prasad S, Bhalerao A, Cucullo L (2019b) NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: molecular mechanisms and possible therapeutic approaches. Redox Biol 21:101059. 10.1016/j.redox.2018.11.017 DOI: 10.1016/j.redox.2018.11.017
Skibinski G, Hwang V, Ando DM et al (2017) Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis. Proc Natl Acad Sci USA 114:1165–1170. 10.1073/pnas.1522872114 DOI: 10.1073/pnas.1522872114
Song Z, Xiong B, Zheng H et al (2017) STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia. Brain Behav Immun 60:161–173. 10.1016/j.bbi.2016.10.009 DOI: 10.1016/j.bbi.2016.10.009
Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. 10.1038/42166 DOI: 10.1038/42166
Staurengo-Ferrari L, Badaro-Garcia S, Hohmann MSN et al (2018) Contribution of Nrf2 modulation to the mechanism of action of analgesic and anti-inflammatory drugs in pre-clinical and clinical stages. Front Pharmacol 9:1536. 10.3389/fphar.2018.01536 DOI: 10.3389/fphar.2018.01536
Tang Y, Le W (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53:1181–1194. 10.1007/s12035-014-9070-5 DOI: 10.1007/s12035-014-9070-5
Tarantini S, Valcarcel-Ares MN, Yabluchanskiy A et al (2018) Nrf2 Deficiency exacerbates obesity-induced oxidative stress, neurovascular dysfunction, blood-brain barrier disruption, neuroinflammation, amyloidogenic gene expression, and cognitive decline in mice, mimicking the aging phenotype. J Gerontol A Biol Sci Med Sci 73:853–863. 10.1093/gerona/glx177 DOI: 10.1093/gerona/glx177
Thimmulappa RK, Lee H, Rangasamy T et al (2006) Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 116:984–995. 10.1172/JCI25790 DOI: 10.1172/JCI25790
Tichauer J, Saud K, von Bernhardi R (2007) Modulation by astrocytes of microglial cell-mediated neuroinflammation: effect on the activation of microglial signaling pathways. NeuroImmunoModulation 14:168–174. 10.1159/000110642 DOI: 10.1159/000110642
Tonelli C, Chio IIC, Tuveson DA (2018) Transcriptional regulation by Nrf2. Antioxid Redox Signal 29:1727–1745. 10.1089/ars.2017.7342 DOI: 10.1089/ars.2017.7342
Troncoso-Escudero P, Parra A, Nassif M, Vidal RL (2018) Outside in: unraveling the role of neuroinflammation in the progression of Parkinson’s disease. Front Neurol 9:860. 10.3389/fneur.2018.00860 DOI: 10.3389/fneur.2018.00860
Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD et al (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101:2040–2045. 10.1073/pnas.0307301101 DOI: 10.1073/pnas.0307301101
Wang C-X, Ge X-Y, Wang M-Y et al (2020) Dopamine D1 receptor-mediated activation of the ERK signaling pathway is involved in the osteogenic differentiation of bone mesenchymal stem cells. Stem Cell Res Ther 11:12. 10.1186/s13287-019-1529-x DOI: 10.1186/s13287-019-1529-x
Wei X, Ma T, Cheng Y et al (2018) Dopamine D1 or D2 receptor-expressing neurons in the central nervous system. Addict Biol 23:569–584. 10.1111/adb.12512 DOI: 10.1111/adb.12512
Xia Q-P, Cheng Z-Y, He L (2019) The modulatory role of dopamine receptors in brain neuroinflammation. Int Immunopharmacol 76:105908. 10.1016/j.intimp.2019.105908 DOI: 10.1016/j.intimp.2019.105908
Zhang Q-S, Heng Y, Yuan Y-H, Chen N-H (2017) Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation. Toxicol Lett 265:30–37. 10.1016/j.toxlet.2016.11.002 DOI: 10.1016/j.toxlet.2016.11.002
Zhou J, Chan L, Zhou S (2012) Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr Med Chem 19:3523–3531. 10.2174/092986712801323171 DOI: 10.2174/092986712801323171
